Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are pregnant are considered a high-risk population, and they face higher rates of ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

Future Cardiol. 2013;9(3):335-349. The efficacy of ambrisentan was demonstrated in the concurrent ARIES-1 and -2 trials. [80] ARIES-1 randomized 202 patients with PAH to either placebo or ...

From sleep deprivation to diabetes prevention, the event included sessions by renowned experts. It underlined the importance ...

Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease ...

Liquidia intends to use the proceeds to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial ... use of YUTREPIA in WHO ...

Corporation has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional ...